BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 5, 2025
Home » Newsletters » BioWorld

BioWorld

Jan. 29, 2015

View Archived Issues

Appointments and advancements

Egalet Corp., of Malvern, Pa., appointed Deanne F. Melloy chief commercial officer. Read More

Financings

Opexa Therapeutics Inc., of The Woodlands, Texas, said it filed a registration statement with the SEC for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common stock and warrants to purchase an additional share of common stock. Read More

In the clinic

Biomay AG, of Vienna, said a landmark phase IIb study has been successfully completed with its third-generation grass pollen allergy vaccine BM32. In this placebo-controlled, double-blind, prospective study, 181 patients were included and initially received either of two doses of BM32 or the matching placebo. Read More

Stock movers

Read More

Other news to note

Amgen Inc., of Thousand Oaks, Calif., and its subsidiary Onyx Pharmaceuticals Inc. submitted a supplemental new drug application (sNDA) to the FDA and a marketing authorization application (MAA) to the EMA seeking approval to market the proteasome inhibitor Kyprolis (carfilzomib) for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Read More

Vaccinogen pads cash; Oncovax re-enters amid immunotherapy fervor

It's been more than six years since 2007 start-up Vaccinogen Inc. licensed rights to Oncovax, a cancer vaccine set to start a confirmatory phase III study in colon cancer. During that time, the immunotherapy space saw more than its share of highs and lows – the excitement surrounding the approval of Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) subsequently crushed by discouraging sales, followed by immunotherapy wins with Bristol-Myers Squibb Co.'s Yervoy (ipilimumab) and the new PD-1 checkpoint inhibitors. Read More

#Path2Cures: Where's the funding for more NIH research?

The conversation has started on the 21st Century Cures discussion draft released Tuesday, with much of it focused on the one thing left out of the nearly 400-page outline of proposals – more funding for the National Institutes of Health (NIH). Read More

Ebola vaccine safe, immunogenic, in Liberia

Initial data from a phase I trial of Glaxosmithkline (GSK) plc's Ebola virus vaccine were published on Wednesday, showing the product is safe and immunogenic. The results were released as the first shipment of the vaccine reached one of the countries hit by the epidemic, with 300 vials arriving in Liberia, West Africa. Read More

EU regulator urges suspension of Indian CRO over data concerns

NEW DELHI, India – The EMA has recommended suspending the Hyderbad-based contract research organisation (CRO) GVK Biosciences on charges of data manipulation, a decision that once again shines a spotlight on the issue of Western drug firms outsourcing clinical trials to CROs to cut costs. Read More

EU obesity stand shifts, diabetes labels sought: Market revival ahead?

Mustering hope in the obesity space – marked by drugs' generally disappointing sales despite a large and growing market – is tough, but Boston-based Zafgen Inc. recently drew investor enthusiasm and pulled off a $138 million public offering to advance what RBC Capital Markets analyst Simos Simeonidis called "a really impressive drug." Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing